The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Relapse and Refractory Patients With CD19+/CD20+ Non-Hodgkin's Lymphoma (NHL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yanyan Liu, M.D. Ph.D
- Phone Number: +8613838176375
- Email: yyliu@zzu.edu.cn
Study Contact Backup
- Name: Zhihua Yao, M.D. Ph.D
- Phone Number: +8613592622292
- Email: zlyyyaozhihua1260@zzu.edu.cn
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
-
Contact:
- Yanyan Liu, M.D. Ph.D
- Phone Number: +8613818176375
- Email: yyliu@zzu.edu.cn
-
Principal Investigator:
- Yanyan Liu, M.D. Ph.D
-
Contact:
- Zhihua Yao, M.D. Ph.D
- Phone Number: +8613592622292
- Email: zlyyyaozhihua1260@zzu.edu.cn
-
Principal Investigator:
- Zhihua Yao, M.D. Ph.D
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 to 75 years old (including 18 and 75)
- Diagnosed as R/R NHL
- CD19/CD20 positive confirmed by cell flow cytometry or immunohistochemistry
- Having at least one measurable lesions
- World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2
- Life expectancy no less than 3 months
- enough main organ function
- Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and 12 months after this study
- Agreeing to sign the written informed consents
Exclusion Criteria:
- Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 12 months
- Active GVHD
- History of severe pulmonary dysfunction
- Active malignant tumor need be treated at the same time
- Uncontrolled active acute/chronic infection
- Severe autoimmune diseases or congenital immunodeficiency
- Untreated active hepatitis
- HIV-positive, AIDS patients and syphilis infection
- History of severe allergies to biological products
- Patients with a history of mental illness
- Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test)
- Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: double-target CART-19 and 20
Patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of double-target CART-19 and 20 cells.
The double-target CART-19 and 20 cells are to be administered on day0.
|
Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
safety as assessed by the occurrence of study related adverse events
Time Frame: from the date of recieving intravenous CART cells up to one month
|
monitor the occurrence of study related adverse events
|
from the date of recieving intravenous CART cells up to one month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
objective response rate
Time Frame: 28 days and 3 months after recieving intravenous CART cells
|
the proportion of patients benefit from the therapy
|
28 days and 3 months after recieving intravenous CART cells
|
|
peripheral blood CART cell copy number
Time Frame: from the date of recieving intravenous CART cells up to one month
|
The highest concentration of CART cells in peripheral blood, the time to reach the highest concentration, and the area under the curve at 28 days after recieving intravenous CART cells
|
from the date of recieving intravenous CART cells up to one month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Zhihua Yao, M.D. Ph.D, Henan Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
Other Study ID Numbers
- Th_C155
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.